Ke Geng


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.


A member of the firm’s Policy Committee and managing partner of the Beijing office, Ke advises clients across numerous industries in connection with financings for Chinese companies, mergers and acquisitions, and other corporate matters.

Ke has been named one of China’s 100 Elite Lawyers by China Business Law Journal for the past two years.  Prior to entering the legal profession, he earned a B.S. degree in Biology from Peking University and a Ph.D. in Biochemistry from New York University.  Ke led the O’Melveny team for RemeGen’s Hong Kong IPO, which was recognized as Deal of the Year by China Business Law Journal and Megatrend Deal of the Year – Healthcare by FinanceAsia.  Ke is highly rated for China capital markets by Chambers Asia Pacific, Chambers Greater China Region and Chambers Global.


  • Mandarin Chinese

Honors & Awards

  • Named to the “A-List” of China’s 100 Elite Foreign Lawyers by China Business Law Journal, 2020 and 2021
  • Recognized by Chambers Global in the practice area of Capital Markets: Equity (International Firms) - China (2022)
  • Recognized by IFLR1000 as a “Notable Practitioner” in the practice area of Mergers & Acquisitions (China) (2019 - 2021)


Bar Admissions

  • New York


  • Northwestern University School of Law, J.D., 2003 
  • New York University, Ph.D., Biochemistry, 2001
  • Peking University, B.S. (Biology), 1994

Professional Activities


  • “Should China Provide Intellectual Property Protection for Genetically Modified Animals?” Northwestern Journal of International Law and Business (Winter 2003) 

Speaking Engagements

  • Practising Law Institute's "Doing Business in and With China 2021" (December, 2021)

Offshore Public Offerings and Capital Markets

Ke regularly advises companies on offshore listings and other capital market financings; his representations amount to an aggregate financing size of over US$20 billion, including:

Life Sciences, Medical and Healthcare:
  • Companies: RemeGen; Akeso Biopharma; Yonghe Medical; Shanghai Bio-heart; Jenscare Scientific; Rainmed; Gushengtang; Acotec Scientific; Brii Biosciences; Keymed Biosciences; Jacobio Pharmaceuticals; Simcere Pharmaceutical; Honliv Healthcare; Hygeia Healthcare; Peijia Medical; Shanghai Kindly Medical Instruments; Pharmaron; Aesthetic Medical International (Nasdaq); Hua Medicine; ShangPharma (NYSE); Viva Biotech; Shanghai Haohai Biological; 3S Bio (Nasdaq), and Phoenix Healthcare
  • Underwriters and Sponsors: Shanghai HeartCare Medical (Goldman Sachs and CICC); Hanyu Medical (on-going), and Wuxi AppTech (NYSE, J.P. Morgan and Credit Suisse)
  • Companies: UP Fintech (Nasdaq); Inc. (NYSE); Inc. (NYSE); Yeahka; eHi Car Services (NYSE), and Montage (Nasdaq)
  • Underwriters and Sponsors: 4Paradigm (on-going, Goldman Sachs and CICC); GDS (J.P. Morgan, BofA Securities, CICC and Haitong International); (NYSE, Morgan Stanley, Credit Suisse and Citigroup); Zhongguancun Science-Tech Leasing (Guotai Junan); FingerTango (China Securities (International) Corporate Finance Company Limited); Digital Hollywood (China Securities (International) Corporate Finance Company Limited); Leju Holdings (NYSE, Credit Suisse and J.P. Morgan, China Renaissance, Macquarie Group and China Merchants Securities); Jupai Holdings (NYSE, Cred3it Suisse and China Renaissance); Tarena Technologies (Nasdaq, Credit Suisse and Goldman Sachs); Zero2IPO (Fortune Financial Capital, Fortune Securities, and CICC), and Chen Lin Education Group (First Shanghai Capital)
    China CITIC Bank; China Construction Bank Corporation; Dexin China; Bank of Qingdao; Hengxing Gold; China Polymetallic Mining; China Real Estate Information Corporation (Nasdaq); Yuzhou Group; Crystal River Capital (NYSE, underwriters), and NorthStar Realty Finance Corp. (NYSE)


In the News

Press Releases

O’Melveny Represents Jenscare Scientific in Its Hong Kong IPO

October 10, 2022

O’Melveny Lawyers and Practice Groups Recommended by IFLR1000 2022-2023 Guide

September 7, 2022

O’Melveny Represents Rainmed Medical in its Hong Kong IPO

July 8, 2022

O’Melveny Receives Top Recognitions from China Business Law Awards 2022

June 16, 2022

Chambers Global Recognizes 29 O’Melveny Lawyers and 11 Practice Groups

February 25, 2022

Geng Ke Named to China’s “A-List” of Elite 100 Lawyers

January 24, 2022

O’Melveny Recommended in China, Korea and Japan by Chambers 2022 Asia-Pacific and Greater China Region Guides

January 13, 2022

O’Melveny Represents Bio-heart in Its Hong Kong IPO

December 23, 2021

O’Melveny Represents Yonghe Medical in US$192 Million Hong Kong IPO

December 13, 2021

O’Melveny Advises Gushengtang in US$104 Million Hong Kong IPO

December 10, 2021

O’Melveny Represents Acotec Scientific in US$210 Million Hong Kong IPO

August 24, 2021

O’Melveny Represents Underwriters in Hong Kong IPO of Shanghai HeartCare Medical Technology Corporation Limited

August 20, 2021

O’Melveny Represents Brii Biosciences in US$318 Million Hong Kong IPO

July 13, 2021

O’Melveny Represents Keymed Biosciences in Approximate US$400 Million Hong Kong IPO

July 8, 2021

O’Melveny Represents Underwriters in US$183 Million Follow-on Public Offering of Tiger Brokers Shares

June 17, 2021

O’Melveny Represents Sponsors and Underwriters in Hong Kong IPO of Zero2IPO

December 30, 2020

O’Melveny Represents JACOBIO in the Final 18A Hong Kong IPO of 2020

December 21, 2020

O’Melveny Recommended for Numerous Practices by Chambers Asia-Pacific 2021 Guide

December 16, 2020